Phase I/II study of ipilimumab for patients with metastatic melanoma

Jeffrey S. Weber, Steven O'Day, Walter Urba, John Powderly, Geoff Nichol, Michael Yellin, Jolie Snively, Evan M Hersh

Research output: Contribution to journalArticle

300 Citations (Scopus)

Abstract

Purpose: The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Secondary objectives included determination of a maximum-tolerated dose and assessment of clinical activity. Patients and Methods: Eighty-eight patients with unresectable stage III or IV melanoma with at least one measurable lesion were treated. Mean age was 59 years, with 65% male and 35% female patients, and 79% of patients had received prior systemic therapy. Single doses of ipilimumab up to 20 mg/kg (group A, single dose), multiple doses up to 5 mg/kg (group A, multiple dose), and multiple doses up to 10 mg/kg (group B) were administered. Results: Single dosing up to 20 mg/kg of transfectoma antibody was well tolerated, as were multiple doses up to 10 mg/kg without a maximum-tolerated dose. In group B, dose-limiting toxicity was seen in six of 23 melanoma patients. Grade 3 or 4 immune-related adverse events (irAEs) were observed in 14% of patients (12 of 88 patients), and grade 1 or 2 irAEs were seen in an additional 58%. The half-life of ipilimumab was 359 hours. In group B, there was one partial response (23+ months), one complete response (21+ months), and seven patients with stable disease (SD), for a disease control rate of 39%. Two patients in group B with SD had slow, steady decline in tumor burden that was ongoing at 1 year of observation. Conclusion: Ipilimumab has activity in patients with metastatic melanoma. Late responses were observed in patients with prolonged SD.

Original languageEnglish (US)
Pages (from-to)5950-5956
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number36
DOIs
StatePublished - Dec 20 2008
Externally publishedYes

Fingerprint

Melanoma
Maximum Tolerated Dose
ipilimumab
Hybridomas
Tumor Burden
Half-Life
Pharmacokinetics
Observation
Safety
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Weber, J. S., O'Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., ... Hersh, E. M. (2008). Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology, 26(36), 5950-5956. https://doi.org/10.1200/JCO.2008.16.1927

Phase I/II study of ipilimumab for patients with metastatic melanoma. / Weber, Jeffrey S.; O'Day, Steven; Urba, Walter; Powderly, John; Nichol, Geoff; Yellin, Michael; Snively, Jolie; Hersh, Evan M.

In: Journal of Clinical Oncology, Vol. 26, No. 36, 20.12.2008, p. 5950-5956.

Research output: Contribution to journalArticle

Weber, JS, O'Day, S, Urba, W, Powderly, J, Nichol, G, Yellin, M, Snively, J & Hersh, EM 2008, 'Phase I/II study of ipilimumab for patients with metastatic melanoma', Journal of Clinical Oncology, vol. 26, no. 36, pp. 5950-5956. https://doi.org/10.1200/JCO.2008.16.1927
Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology. 2008 Dec 20;26(36):5950-5956. https://doi.org/10.1200/JCO.2008.16.1927
Weber, Jeffrey S. ; O'Day, Steven ; Urba, Walter ; Powderly, John ; Nichol, Geoff ; Yellin, Michael ; Snively, Jolie ; Hersh, Evan M. / Phase I/II study of ipilimumab for patients with metastatic melanoma. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 36. pp. 5950-5956.
@article{10d01d77287145d3b149123a004fa868,
title = "Phase I/II study of ipilimumab for patients with metastatic melanoma",
abstract = "Purpose: The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Secondary objectives included determination of a maximum-tolerated dose and assessment of clinical activity. Patients and Methods: Eighty-eight patients with unresectable stage III or IV melanoma with at least one measurable lesion were treated. Mean age was 59 years, with 65{\%} male and 35{\%} female patients, and 79{\%} of patients had received prior systemic therapy. Single doses of ipilimumab up to 20 mg/kg (group A, single dose), multiple doses up to 5 mg/kg (group A, multiple dose), and multiple doses up to 10 mg/kg (group B) were administered. Results: Single dosing up to 20 mg/kg of transfectoma antibody was well tolerated, as were multiple doses up to 10 mg/kg without a maximum-tolerated dose. In group B, dose-limiting toxicity was seen in six of 23 melanoma patients. Grade 3 or 4 immune-related adverse events (irAEs) were observed in 14{\%} of patients (12 of 88 patients), and grade 1 or 2 irAEs were seen in an additional 58{\%}. The half-life of ipilimumab was 359 hours. In group B, there was one partial response (23+ months), one complete response (21+ months), and seven patients with stable disease (SD), for a disease control rate of 39{\%}. Two patients in group B with SD had slow, steady decline in tumor burden that was ongoing at 1 year of observation. Conclusion: Ipilimumab has activity in patients with metastatic melanoma. Late responses were observed in patients with prolonged SD.",
author = "Weber, {Jeffrey S.} and Steven O'Day and Walter Urba and John Powderly and Geoff Nichol and Michael Yellin and Jolie Snively and Hersh, {Evan M}",
year = "2008",
month = "12",
day = "20",
doi = "10.1200/JCO.2008.16.1927",
language = "English (US)",
volume = "26",
pages = "5950--5956",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Phase I/II study of ipilimumab for patients with metastatic melanoma

AU - Weber, Jeffrey S.

AU - O'Day, Steven

AU - Urba, Walter

AU - Powderly, John

AU - Nichol, Geoff

AU - Yellin, Michael

AU - Snively, Jolie

AU - Hersh, Evan M

PY - 2008/12/20

Y1 - 2008/12/20

N2 - Purpose: The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Secondary objectives included determination of a maximum-tolerated dose and assessment of clinical activity. Patients and Methods: Eighty-eight patients with unresectable stage III or IV melanoma with at least one measurable lesion were treated. Mean age was 59 years, with 65% male and 35% female patients, and 79% of patients had received prior systemic therapy. Single doses of ipilimumab up to 20 mg/kg (group A, single dose), multiple doses up to 5 mg/kg (group A, multiple dose), and multiple doses up to 10 mg/kg (group B) were administered. Results: Single dosing up to 20 mg/kg of transfectoma antibody was well tolerated, as were multiple doses up to 10 mg/kg without a maximum-tolerated dose. In group B, dose-limiting toxicity was seen in six of 23 melanoma patients. Grade 3 or 4 immune-related adverse events (irAEs) were observed in 14% of patients (12 of 88 patients), and grade 1 or 2 irAEs were seen in an additional 58%. The half-life of ipilimumab was 359 hours. In group B, there was one partial response (23+ months), one complete response (21+ months), and seven patients with stable disease (SD), for a disease control rate of 39%. Two patients in group B with SD had slow, steady decline in tumor burden that was ongoing at 1 year of observation. Conclusion: Ipilimumab has activity in patients with metastatic melanoma. Late responses were observed in patients with prolonged SD.

AB - Purpose: The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Secondary objectives included determination of a maximum-tolerated dose and assessment of clinical activity. Patients and Methods: Eighty-eight patients with unresectable stage III or IV melanoma with at least one measurable lesion were treated. Mean age was 59 years, with 65% male and 35% female patients, and 79% of patients had received prior systemic therapy. Single doses of ipilimumab up to 20 mg/kg (group A, single dose), multiple doses up to 5 mg/kg (group A, multiple dose), and multiple doses up to 10 mg/kg (group B) were administered. Results: Single dosing up to 20 mg/kg of transfectoma antibody was well tolerated, as were multiple doses up to 10 mg/kg without a maximum-tolerated dose. In group B, dose-limiting toxicity was seen in six of 23 melanoma patients. Grade 3 or 4 immune-related adverse events (irAEs) were observed in 14% of patients (12 of 88 patients), and grade 1 or 2 irAEs were seen in an additional 58%. The half-life of ipilimumab was 359 hours. In group B, there was one partial response (23+ months), one complete response (21+ months), and seven patients with stable disease (SD), for a disease control rate of 39%. Two patients in group B with SD had slow, steady decline in tumor burden that was ongoing at 1 year of observation. Conclusion: Ipilimumab has activity in patients with metastatic melanoma. Late responses were observed in patients with prolonged SD.

UR - http://www.scopus.com/inward/record.url?scp=58049202334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049202334&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.16.1927

DO - 10.1200/JCO.2008.16.1927

M3 - Article

C2 - 19018089

AN - SCOPUS:58049202334

VL - 26

SP - 5950

EP - 5956

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -